Bylaw Amendment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________   FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): May 19, 2025         THE CLOROX COMPANY (Exact name of registrant as specified in its charter) __________________   Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation)   Identification No.) 1221 Broadway , Oakland , California 94612-1888 (Address of principal executive offices) (Zip code)   ( 510 ) 271-7000 (Registrant's telephone number, including area code)   Not applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock - $1.00 par value CLX New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).   Emerging growth company      ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐           Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year   The Board of Directors of The Clorox Company (the “Company”) amended and restated the Company’s bylaws (the “Bylaws”), effective May 19, 2025. The amendments implement a cure process for certain deficiencies in director nomination notices submitted by shareholders. For nomination notices received by the Company within the time period specified in the Bylaws, the Company will notify shareholders of deficiencies in the notice and there will be an opportunity to cure such deficiencies within the time period specified.   This description of the amendments to the Bylaws is not complete and is qualified in its entirety by reference to the text of the Bylaws filed as Exhibit 3.2 to this Report.   Item 9.01 Financial Statements and Exhibits   (d) Exhibits   See the Exhibit Index below.   EXHIBIT INDEX   Exhibit   Description 3.2   Amended and Restated Bylaws 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)   2     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       THE CLOROX COMPANY   Date:  May 23, 2025 By: /s/ Angela Hilt       Angela Hilt       Executive Vice President – Chief Legal and External Affairs Officer and Corporate Secretary         3